Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Valeant Will Become Bausch Health Companies Inc.
Valeant Will Become Bausch Health Companies Inc.
AVAL, Quebec, May 8, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Tokyo, Munich, and Basking Ridge, NJ – (May 8, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announces that the pivotal QuANTUM-R phase 3 study of single ag...
Lilly Announces Agreement To Acquire ARMO BioSciences
Lilly Announces Agreement To Acquire ARMO BioSciences
INDIANAPOLIS and REDWOOD CITY, Calif.
Portola's Andexxa bleeding antidote wins FDA nod but will see limited release
Portola's Andexxa bleeding antidote wins FDA nod but will see limited release
Portola has finally overcome FDA concerns to win approval of its coagulation factor Xa, a bleeding antidote for some of the new generation blood thinners like Xarelto and Eliquis.
South Africa's Aspen opens $80M high potency site, adding 500 workers
South Africa's Aspen opens $80M high potency site, adding 500 workers
South Africa’s Aspen Pharmacare is expanding into complex meds for cancer and other conditions and has just opened an $80 million facility that can produce them, adding about 500 jobs in the process...
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report
As Novartis tries to shed some of its Sandoz offerings in the U.
Japan's Takeda clinches $62 billion deal to buy drugmaker Shire
Japan's Takeda clinches $62 billion deal to buy drugmaker Shire
Takeda Pharma agreed to buy London-listed Shire for 45.
Bayer sells further Covestro stake for 2.2 billion euros
Bayer sells further Covestro stake for 2.2 billion euros
BERLIN (Reuters) - Pharmaceutical group Bayer (BAYGn.
Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.
Back U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors
Back U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors
SOUTH SAN FRANCISCO, Calif.
Celgene Reports First Quarter 2018 Operating and Financial Results
Celgene Reports First Quarter 2018 Operating and Financial Results
SUMMIT, N.
After FDA rebuff, Celgene on track to refile ozanimod — in 2019
After FDA rebuff, Celgene on track to refile ozanimod — in 2019
Celgene suffered an embarrassing setback in February when it got a refuse-to-file letter for its multiple sclerosis drug ozanimod.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand